Fresh Tracks Therapeutics, Inc. Common Stock
FRTX
FRTX was delisted on the 18th of December, 2023.
15 hedge funds and large institutions have $456K invested in Fresh Tracks Therapeutics, Inc. Common Stock in 2023 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 4 closing their positions.
553% more capital invested
Capital invested by funds: $69.8K → $456K (+$386K)
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
0% more funds holding
Funds holding: 15 → 15 (0)
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JC
JBF Capital
Aspen,
Colorado
|
+$209K |
| 2 |
GS
GTS Securities
New York
|
+$35.4K |
| 3 |
VF
Virtu Financial
New York
|
+$21.7K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$18.9K |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$9 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSS
Two Sigma Securities
New York
|
-$7.94K |
| 2 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$7.1K |
| 3 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$7.01K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$180 |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$2 |
FRTX Hedge Fund Activity: Q3 2023 in Review
15 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) for Q3 2023, worth a combined $456K — up 553% from $69.8K a quarter earlier.
Fund positioning in FRTX was balanced in Q3 2023: 4 funds opened new positions, 4 closed out, 3 added to existing stakes and 1 trimmed.
The largest buyer was JBF Capital, opening a new position worth an estimated $209K. The largest seller was Two Sigma Securities, exiting entirely with an estimated $7.94K sold.
- 15 institutional investors held Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) as of Q3 2023, unchanged from Q2 2023.
- Funds reported $456K of Fresh Tracks Therapeutics, Inc. Common Stock stock for Q3 2023, up 553% quarter-over-quarter.
- 4 funds opened new Fresh Tracks Therapeutics, Inc. Common Stock positions in Q3 2023 and 4 closed out, a net change of 0 holders.
- The largest Fresh Tracks Therapeutics, Inc. Common Stock buyer in Q3 2023 was JBF Capital, an estimated $209K added.
- The largest Fresh Tracks Therapeutics, Inc. Common Stock seller in Q3 2023 was Two Sigma Securities, an estimated $7.94K sold.
Based on aggregated 13F filings for Q3 2023.